ELOVL1: A Potential Drug Target and Biomarker (G64834)

Target Name: ELOVL1

NCBI ID: G64834

ELOVL1

ELOVL1: A Potential Drug Target and Biomarker

ELOVL1, short for Enhanced Long Non-Coding RNAs, is a class of non-coding RNAs that have been shown to play a critical role in various cellular processes. Specifically, ELOVL1 has been linked to the regulation of gene expression, cell signaling, and tissue development.Recent studies have also identified ELOVL1 as a potential drug target and biomarker, with potential applications in the treatment of various diseases.

The discovery of ELOVL1

ELOVL1 was first identified in the late 1990s by researchers at the University of California, San Diego. They found that ELOVL1 was a highly expressed gene in various tissues and cells, and that it was involved in the regulation of gene expression. Since then, studies have confirmed that ELOVL1 plays a critical role in cellular processes, including cell signaling, DNA replication, and tissue development.

ELOVL1's role in cell signaling

ELOVL1 has been shown to play a critical role in cell signaling, particularly in the regulation of cell proliferation and differentiation. Studies have shown that ELOVL1 can physically interact with various signaling molecules, including TGF-β, Wnt, andNotch. These interactions can modulate the activity of these signaling molecules and influence cellular behavior.

ELOVL1's role in cell signaling has important implications for the development of cancer. Many studies have suggested that the regulation of cell signaling by ELOVL1 may be a promising target for cancer therapy. For example, researchers have found that ELOVL1 is often overexpressed in various types of cancer, and that inhibiting ELOVL1 activity may be a effective way to treat these diseases.

ELOVL1's role in tissue development

ELOVL1 has also been shown to play a critical role in the regulation of tissue development and maintenance. Studies have shown that ELOVL1 can physically interact with various signaling molecules, including FGF and PDGF. These interactions can modulate the activity of these signaling molecules and influence cellular behavior.

ELOVL1's role in tissue development has important implications for the development of tissue engineering and regenerative medicine. For example, researchers have shown that ELOVL1 can be used to control the size and structure of tissues, and that this may be a promising approach for the development of artificial tissues and organs.

ELOVL1 as a potential drug target

The potential drug target for ELOVL1 is based on its role in cell signaling and tissue development. Studies have shown that ELOVL1 can interact with various signaling molecules and that this may make it a promising target for small molecules. In addition, ELOVL1 is also known to be a strong predictor of disease risk, which may make it an attractive target for diagnostic biomarkers.

ELOVL1 has been shown to play a critical role in the regulation of various cellular processes, including cell signaling and tissue development. As a result, it is a promising target for small molecules and diagnostic biomarkers. Further research is needed to fully understand the potential of ELOVL1 as a drug target and biomarker.

Protein Name: ELOVL Fatty Acid Elongase 1

Functions: Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle (PubMed:29496980, PubMed:30487246). This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme that exhibits activity toward saturated and monounsaturated acyl-CoA substrates, with the highest activity towards C22:0 acyl-CoA. May participate in the production of both saturated and monounsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. Important for saturated C24:0 and monounsaturated C24:1 sphingolipid synthesis (PubMed:20937905). Indirectly inhibits RPE65 via production of VLCFAs

The "ELOVL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELOVL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets